Skip to content

Genetic Identification of Monogenic Disorders in Early-onset Stroke Using Targeted Next Generation Sequencing Panel

Genetic Identification of Monogenic Disorders in Early-onset Stroke Using Targeted Next Generation Sequencing Panel

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04485598
Acronym
MDEOS
Enrollment
502
Registered
2020-07-24
Start date
2015-08-21
Completion date
2020-05-22
Last updated
2020-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Single-gene Disorders, Stroke, Acute, Transient Ischemic Attack

Keywords

Stroke, Transient Ischemic Attack, Targeted sequencing panel, Early-onset

Brief summary

The study was designed as a multicenter multiracial prospective observational study of acute ischemic stroke and TIA patients across china. The purpose of this study is to determine the monogenic disorders incidence of Chinese early-onset stroke patients. We plan to consecutively enroll more than 500 patients with early-onset stroke(in the 18- to 45-year age range) admitted in stroke units within 7 days after symptoms onset in participating centers. These early-onset stroke patients are referred for targeted sequencing using 'cerebrovascular disease panel'. By analyzing the sequencing results, we intend to identify monogenic causes causing early-onset stroke and develop clinical algorithms that might assist the clinician in deciding in which early-onset stroke patients testing for monogenic causes of stroke.

Detailed description

The study was designed as a multicenter multiracial prospective observational study of acute ischemic stroke and TIA patients across china. The purpose of this study is to determine the monogenic disorders incidence of Chinese early-onset stroke patients. We plan to consecutively enroll more than 500 patients with early-onset stroke(in the 18- to 45-year age range) admitted in stroke units within 7 days after symptoms onset in participating centers. Patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be referred for targeted sequencing using 'cerebrovascular disease panel'. When one or multiple pathogenic or possible pathogenic exonic mutations are found, a Sanger Sequencing (SS) on somatic DNA from peripheral blood leukocyte of the index case and affected relatives will be performed for the screening of the same mutations. And the sporadic patient's mutations will be checked by SS in the unaffected family members. By analyzing the sequencing results, we intend to identify monogenic causes causing early-onset stroke and develop clinical algorithms that might assist the clinician in deciding in which early-onset stroke patients testing for monogenic causes of stroke.

Interventions

None listed

Sponsors

Beijing Municipal Science & Technology Commission
CollaboratorOTHER
Beijing Tiantan Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Provision of informed consent. * Female or male aged ≥ 18 years and ≤ 45 years. * Acute ischemic stroke or Transient ischemic attack((Neurological deficit attributed to focal brain ischemia, with resolution of the deficit within 24 hours of symptom onset) patients that can be enrolled within 7 days of symptoms onset defined by thelast see normalprinciple.

Exclusion criteria

* Asymptomatic brain infarction * Neurological deficit due to causes other than ischemic stroke or TIA

Design outcomes

Primary

MeasureTime frameDescription
Percentage of patients with certain etiologic diagnosis established with targeted sequencingday 0Percentage of patients with certain etiologic diagnosis established with targeted sequencing

Secondary

MeasureTime frameDescription
Obtained read depth according to number of pooled samplesday 0Obtained read depth according to number of pooled samples
Percentage of patients with variant with unknown significanceday 0Percentage of patients with variant with unknown significance, needing supplementary analyses to prove its involvement in early-onset stroke
Clinical phenotype for each gene for which a causal mutation is identified by targeted sequencing panelday 0Clinical phenotype for each gene for which a causal mutation is identified by targeted sequencing panel
Time of analysis of NGS raw data30 daysTime of analysis of NGS raw data
Incidence of certain single-gene disorders in early-onset stroke patientsday 0Incidence of certain single-gene disorders in early-onset stroke patients

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026